M. Makrutzki

发表

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

A. Hauschild, P. Ascierto, J. Larkin, 2017, European journal of cancer.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

J. Blay, M. Hidalgo, J. Baselga, 2015, The New England journal of medicine.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

R. Greil, S. Kubicka, E. Van Cutsem, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

A. Hauschild, D. Schadendorf, R. Gonzalez, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.

E. Van Cutsem, J. Tabernero, M. Makrutzki, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

J. Hecht, R. Salazar, E. Van Cutsem, 2012, The Lancet. Oncology.

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

David M. Hyman, Vivek Subbiah, Jordi Rodon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

J. Pichler, W. Mason, A. Brandes, 2018, The oncologist.

Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study

J. Blay, J. Baselga, O. Abdel-Wahab, 2017, JAMA oncology.

Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study

J. Blay, J. Baselga, Gregory Riely, 2019, JCO precision oncology.

Quality‐of‐life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient‐reported outcomes from the MIKIE study

A. Hauschild, D. Schadendorf, S. Puig, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

A. Hauschild, P. Ascierto, J. Larkin, 2019, European journal of cancer.

Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study.

J. Blay, J. Baselga, J. Tabernero, 2018, JCO precision oncology.

Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

J. Blay, J. Baselga, J. Tabernero, 2015 .

A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial.

R. Salazar, E. Van Cutsem, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

J. Blay, J. Baselga, O. Abdel-Wahab, 2016 .

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

R. Greil, S. Kubicka, M. Makrutzki, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.